Navigation Links
Access Pharmaceuticals Receives Letter of Acceptance For MuGard Filing From SFDA of China
Date:6/17/2011

DALLAS and NEW YORK, June 17, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, announced that its MuGard partner in China, RHEI Pharmaceuticals has received the acceptance letter from the State Food and Drug Administration (SFDA) of China acknowledging all necessary documentation for the MuGard has been submitted and accepted.  Together with its marketing partner Jian An, RHEI Pharmaceuticals completed the required process required to satisfy all requirements to receive marketing approval in China and its other South East Asian territories.  RHEI has advised Access of the next steps the SFDA will take to grant approval in its territories and anticipates receiving marketing approval in the second half of this year.

As part of its licensing agreement with Access, RHEI is responsible for obtaining the necessary regulatory approvals for MuGard.  Access and RHEI recently signed a $30 million supply agreement for MuGard to ensure manufacturing capacity of up to a minimum of $30 million of product in the licensed territories. In addition, Access also approved a sub-license agreement between RHEI Pharmaceuticals and Jian An Pharmaceuticals ("Jian An") Limited in Shenzhen, China to leverage Jian An's extensive sales, marketing and regulatory infrastructure for the launch of MuGard in China and Taiwan. Jian An is headquartered in Shenzhen, China and has a 25-year history of selling pharmaceutical and other medical products in the China market.  Jian An has 1400 sales representatives covering all majors centers in China through 169 sales offices.  

With Jian An's sales and marketing infrastructure, the supply agreement and the letter of acceptance, Access Pharmaceuticals' commercialization efforts remain on track in China.
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
2. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
3. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
4. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
5. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
8. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
11. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... -- Sony Biotechnology Inc. ("Sony") today announced the launch of ... be exhibiting and taking orders for this system at ... San Diego Convention Center in ... - 22.  The SP6800 Spectral Analyzer ... into new and novel functionalities for the immunology, oncology, ...
(Date:5/17/2013)...  TechAtlas Group has announced the release of ... for the Chronic Kidney Disease (CKD) market. This ... drugs and devices currently on the market and ... (Logo:  http://photos.prnewswire.com/prnh/20130517/NE16011LOGO ) ... renal denervation , diabetic nephropathy - antifibrotics ...
(Date:5/17/2013)... PONCE , Puerto Rico , May ... southern, central and western Puerto Rico , ... , PR) Center has improved its radiation therapy capabilities with ... in Puerto Rico . Versa HD offers ... wide range of tumors throughout the body, while also enabling ...
Breaking Medicine Technology:Sony Biotechnology Inc.'s New Technology for Science Provides Researchers Results in Color 2TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2Puerto Rico's Caribbean Imaging and Radiation Therapy Center Orders Elekta's New Versa HD System for Treatment of Cancer Patients 2
... 11, 2007 /PRNewswire-FirstCall/ - Paul S.,Aisen, M.D., ... Medical Center, and principal investigator in the ... III clinical trial,for tramiprosate (ALZHEMED(TM)) will present ... for the treatment of,Alzheimer's disease (AD). The ...
... /PRNewswire/ -- Sugammadex -,the novel selective relaxant binding ... business unit of Akzo Nobel -,demonstrated in a ... of neuromuscular blockade as compared to neostigmine,without evidence ... muscle relaxation.(1),(2) The results of this,pivotal Aurora trial ...
Cached Medicine Technology:At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed) 2At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed) 3At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed) 4Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in,Phase III Pivotal Trial as Compared to Neostigmine 2Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in,Phase III Pivotal Trial as Compared to Neostigmine 3Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in,Phase III Pivotal Trial as Compared to Neostigmine 4
(Date:5/20/2013)... 20, 2013 Milpitas, Los Angeles, ... leader in enterprise-class information archiving, eDiscovery and migration ... 7.0, the latest release in the MessageSolution product ... the legal discovery lifecycle. MessageSolution will exhibit at ... CA. , As the first stop of the ...
(Date:5/20/2013)... InVite® Health, a leading nutraceutical firm ... of its new Greens Hx™ product; a ... with plant extracts from 39 super foods including sea ... pectin, plant enzymes and non-dairy probiotics. A small ... levels of several servings of vegetables. The product is ...
(Date:5/20/2013)... May 20, 2013 The transvaginal mesh ... device law firm, report that two important bellwether trials ... in state and federal litigations established for C.R. Bard ... the first C.R. Bard bellwether trial will begin in ... of West Virginia. (In re: C.R. Bard, Inc., ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 Today is ... Perfect Interview Answers Webinar tomorrow. Job seekers ... Career Confindential’s expert career coach, will show job seekers ... Webinar attendees will also learn the perfect interview answers ... as interview techniques that will get them hired. Job ...
(Date:5/19/2013)... California has one of the largest pool of ... discovering that comprehensive background checks are playing an important role ... Driving records can paint an accurate portrait of a ... any DUI arrests, speeding offenses, and traffic violations to their ... to experience 4SafeDrivers.com, a new online service which allows users ...
Breaking Medicine News(10 mins):Health News:MessageSolution Releases Enterprise eDiscovery Platform 7.0 at LegalTech 2013 West Coast Expo 2Health News:MessageSolution Releases Enterprise eDiscovery Platform 7.0 at LegalTech 2013 West Coast Expo 3Health News:MessageSolution Releases Enterprise eDiscovery Platform 7.0 at LegalTech 2013 West Coast Expo 4Health News:InVite® Health Introduces New Food-Based Dietary Supplement – Greens Hx™ 2Health News:InVite® Health Introduces New Food-Based Dietary Supplement – Greens Hx™ 3Health News:Transvaginal Mesh Lawyers at Wright & Schulte LLC Look Ahead to Upcoming Vaginal Mesh Lawsuit Bellwether Trials 2Health News:Transvaginal Mesh Lawyers at Wright & Schulte LLC Look Ahead to Upcoming Vaginal Mesh Lawsuit Bellwether Trials 3Health News:Transvaginal Mesh Lawyers at Wright & Schulte LLC Look Ahead to Upcoming Vaginal Mesh Lawsuit Bellwether Trials 4Health News:Today Is the Last Day to Register for Tomorrow’s Perfect Interview Answers Webinar From Career Confidential 2Health News:4SafeDrivers.com Announces Driving Record Searches for California Employers 2
... ANN ARBOR, Mich.---Apparently your mom had it right when she ... talked dirty. Lying really does create a desire to clean ... study. "The references to ,dirty hands, or ,dirty mouths, ... of moral purity in terms of more concrete experiences with ...
... at the Indiana University Melvin and Bren Simon Cancer ... show that changes in brain tissue can occur in ... of chemotherapy, often referred to as "chemobrain," have been ... the first to use brain imaging to study women ...
... , CHAPEL HILL, N.C. -- A team of UNC ... National Cancer Institute,s Cancer Nanotechnology Platform Partnerships to address ... effective treatments for pancreatic cancer. Wenbin Lin, PhD, ... MD, assistant professor of surgery and pharmacology, are the ...
... between the increase in sales of new antidepressants in recent ... a study based on figures from the Nordic countries, researchers ... that increased sales of the new medicines could be linked ... find any relationship between reduced sales of the older and ...
... UN Millennium Development Goals (MDG) summit in New York ... the eight goals agreed in 2000 on alleviating world ... to a close, governments, businesses and aid organisations made ... emphasis on improving maternal and child health. A global ...
... Reporter , TUESDAY, Sept. 28 (HealthDay News) -- Think recess, ... break in the school day set aside for running and ... adult life. What if your workplace started offering recess on ... a good idea but possibly one of the most solid ...
Cached Medicine News:Health News:Dirty hands, dirty mouths: U-M study finds a need to clean the body part that lies 2Health News:IU researchers: Chemotherapy alters brain tissue in breast cancer patients 2Health News:Decrease in suicide not linked to newer antidepressants 2Health News:International AIDS Society emphasizes universal access to HIV prevention, treatment and care as a prerequisite for improving maternal and child health 2Health News:International AIDS Society emphasizes universal access to HIV prevention, treatment and care as a prerequisite for improving maternal and child health 3Health News:Adding Recess to the Workday Gains Backers 2Health News:Adding Recess to the Workday Gains Backers 3Health News:Adding Recess to the Workday Gains Backers 4
The entirely open modular system is especially suitable for stereotactic microsurgical procedures....
Used to negotiate tortuous vessels....
The Emerald Guidewire is intended for percutaneous introduction of catheters....
... The MULTI-LINK VISION Coronary Stent System is ... cobalt chromium stents. Cobalt chromium is stronger ... a cobalt chromium stent can have similar ... steel stent with struts that are only ...
Medicine Products: